0LC7
vs
S&P 500
0LC7
S&P 500
Over the past 12 months, 0LC7 has underperformed S&P 500, delivering a return of -63% compared to the S&P 500's +38% growth.
Stocks Performance
0LC7 vs S&P 500
Performance Gap
0LC7 vs S&P 500
Performance By Year
0LC7 vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Syros Pharmaceuticals Inc
Glance View
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2016-06-30. The firm is focused on redefending the power of small molecules to control the expression of genes. The firm is engaged in developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical-stage pipeline of gene control medicine. The firm's lead product candidates include Tamibarotene, SY-2101 and SY-5609. Its Tamibarotene, is a selective retinoic acid receptor alpha (RARα), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). Its SY-5609, is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being development for patients with select solid tumors and blood cancers.
